GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
I

Inner Mongolia Furui Medical Science Co 300049.SZ · CNY

Health Care · Shenzhen · 🇨🇳 China

Compare

46.81

-2.26%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥1.59bn

FY2016FY2025

Net income

CN¥154.1m

FY2016FY2025

Free cash flow

CN¥165.1m

FY2016FY2025

Shareholders' equity

CN¥1.98bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥1.59bnCN¥1.35bnCN¥1.15bnCN¥1.01bnCN¥898.5mCN¥807.5mCN¥831.7mCN¥867.0mCN¥823.3mCN¥827.0m
Gross profitCN¥1.09bnCN¥998.3mCN¥862.3mCN¥741.1mCN¥659.3mCN¥580.9mCN¥592.7mCN¥606.1mCN¥606.4mCN¥596.1m
Research and developmentCN¥77.0mCN¥105.1mCN¥82.5mCN¥70.8mCN¥64.8mCN¥65.8mCN¥60.7mCN¥64.7mCN¥60.3mCN¥46.9m
Operating incomeCN¥399.7mCN¥277.9mCN¥253.1mCN¥192.7mCN¥188.8mCN¥119.7mCN¥127.1mCN¥123.3mCN¥139.2mCN¥175.9m
Net incomeCN¥154.1mCN¥113.3mCN¥101.6mCN¥97.9mCN¥95.5mCN¥61.9mCN¥43.4mCN¥35.4mCN¥61.1mCN¥121.0m
Diluted earnings per share0.590.430.390.370.360.240.190.120.190.48

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥3.44bnCN¥3.06bnCN¥2.65bnCN¥2.52bnCN¥2.52bnCN¥2.29bnCN¥2.25bnCN¥2.14bnCN¥2.51bnCN¥2.41bn
Cash and short-term investmentsCN¥733.4mCN¥724.3mCN¥603.7mCN¥615.4mCN¥618.5mCN¥515.9mCN¥435.2mCN¥298.9mCN¥787.6mCN¥867.8m
Total liabilitiesCN¥652.2mCN¥931.0mCN¥800.1mCN¥697.3mCN¥719.0mCN¥675.0mCN¥698.7mCN¥622.5mCN¥594.4mCN¥581.2m
DebtCN¥137.1mCN¥55.2mCN¥44.9mCN¥43.0mCN¥94.1mCN¥115.2mCN¥108.7mCN¥78.5mCN¥85.0mCN¥70.2m
Shareholders' equityCN¥1.98bnCN¥1.75bnCN¥1.55bnCN¥1.55bnCN¥1.52bnCN¥1.35bnCN¥1.32bnCN¥1.33bnCN¥1.50bnCN¥1.46bn
Shares outstanding263m265m263m263m263m256m223m291m327m252m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥354.1mCN¥221.4mCN¥304.9mCN¥189.5mCN¥222.6mCN¥200.2mCN¥256.2mCN¥78.3mCN¥131.7mCN¥148.8m
Capital spending−CN¥189.0m−CN¥219.0m−CN¥189.2m−CN¥90.8m−CN¥79.6m−CN¥109.7m−CN¥66.3m−CN¥94.0m−CN¥39.6m−CN¥213.5m
Free cash flowCN¥165.1mCN¥2.4mCN¥115.7mCN¥98.7mCN¥142.9mCN¥90.4mCN¥189.9m−CN¥15.6mCN¥92.1m−CN¥64.7m
Dividends paid−CN¥2.3m−CN¥2.2m−CN¥53.4m−CN¥71.4m−CN¥1.9m−CN¥3.8m−CN¥3.0m−CN¥31.1m−CN¥32.3m−CN¥27.8m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥394.6mCN¥360.1mCN¥494.3mCN¥387.6mCN¥383.0mCN¥330.4mCN¥369.2mCN¥337.2m
Gross profitCN¥302.1mCN¥269.7mCN¥340.6mCN¥291.7mCN¥283.4mCN¥253.6mCN¥248.7mCN¥259.3m
Operating incomeCN¥84.7mCN¥73.8mCN¥141.0mCN¥109.3mCN¥55.4mCN¥62.9mCN¥64.1mCN¥66.4m
Net incomeCN¥32.1mCN¥31.8mCN¥42.2mCN¥60.0mCN¥23.3mCN¥28.6mCN¥11.3mCN¥26.6m
Diluted earnings per share0.120.120.160.230.090.110.040.10
Cash from operations——CN¥139.0mCN¥78.0mCN¥59.0mCN¥76.0mCN¥99.0mCN¥16.0m
Capital spending−CN¥31.0m−CN¥48.0m−CN¥48.0m−CN¥37.0m−CN¥48.0m−CN¥54.0m−CN¥72.0m−CN¥65.0m
Free cash flow——CN¥91.0mCN¥41.0mCN¥11.0mCN¥22.0mCN¥27.0m−CN¥49.0m
Total assetsCN¥3.47bnCN¥3.42bnCN¥3.44bnCN¥3.21bnCN¥3.16bnCN¥3.08bnCN¥3.06bnCN¥2.82bn
Cash and short-term investments——CN¥733.4mCN¥734.4mCN¥715.7mCN¥726.2mCN¥724.3mCN¥547.3m
DebtCN¥44.4mCN¥10.0mCN¥67.7mCN¥30.4mCN¥67.5mCN¥27.0m——
Shareholders' equityCN¥1.97bnCN¥1.98bnCN¥1.98bnCN¥1.91bnCN¥1.82bnCN¥1.78bnCN¥1.75bnCN¥1.60bn

Financial ratios

Data as of 29 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Gross margin68.3%74.0%74.7%73.5%73.4%71.9%—
Operating margin25.1%20.6%21.9%19.1%21.0%14.8%—
Net margin9.7%8.4%8.8%9.7%10.6%7.7%—
Return on equity7.8%6.5%6.6%6.3%6.3%4.6%—
Return on assets4.5%3.7%3.8%3.9%3.8%2.7%—
Free cash flow yield4.5%3.6%4.1%2.3%2.5%2.6%—
Revenue growth18.1%16.9%14.4%12.3%11.3%-2.9%—
Earnings growth36.0%11.5%3.8%2.5%54.2%42.7%—
Current ratio3.20x4.12x4.21x5.20x4.18x4.20x—
Debt to equity0.03x—0.01x0.00x0.03x0.04x0.04x
Equity ratio57.5%57.1%58.4%61.3%60.2%59.0%—
Interest coverage112.47x93.38x177.65x106.03x73.05x37.29x—
R&D as a share of sales4.8%7.8%7.1%7.0%7.2%8.2%—
Buybacks as a share of market value0.9%-1.0%0.1%-0.0%-2.6%-15.0%—

Growth per year

Compound annual rate

3 years5 years10 years
Revenue16.4%14.6%10.2%
Operating income27.5%27.3%12.7%
Net income16.3%20.0%5.3%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin70.9%72.3%72.4%71.9%
Operating margin23.0%22.0%21.0%19.7%
Net margin9.1%9.1%9.2%9.1%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings120.273.9112.865.740.533.839.183.371.443.6
Price to sales11.66.29.96.44.32.62.03.45.36.4

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 13 Jun 2023.

FY2023FY2018FY2017FY2016FY2015FY2012FY2011FY2010
Paid in the year0.200.100.100.100.100.150.1150.089
  • 2-for-1 split · 6 Jul 2015
  • 13-for-10 split · 4 May 2011
  • 13-for-10 split · 30 Sept 2010

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.